Komori
Share Issuance and Disposal4564OncoTherapy Science,Inc.Pharmaceuticals

新株予約権引受契約に基づく第38回新株予約権(行使価額修正条項付)の行使停止要請通知に関するお知らせ

会社が、第38回新株予約権の未行使残りすべてについて、2026年3月27日から3月31日まで行使を停止するよう割当先に要請した。

Worth reading
61In focus
Scored from 2 of 5 sections
Direction
Neutral
Direction inferred from the company’s description.
Scale
39600000
Common shares
Wording
Definitive
How definitive the wording is.

Details of issuance or disposal

行使価額修正条項付新株予約権の行使停止要請

Intended allottee
Name Long Corridor Alpha Opportunities Master Fund / Number of Shares Not disclosed, Name MAP246 Segregated Portfolio / Number of Shares Not disclosed, Name BEMAP Master Fund Ltd. / Number of Shares Not disclosed
Terms of the stock acquisition rights
Number of Stock Acquisition Rights
発行総数:Not disclosed、未行使残:396,000個(普通株式39,600,000株)
Most recent equity financing
Timing 8 December 2025 / Type 第三者割当による新株式及び第38回新株予約権(行使価額修正条項付)の発行 / Amount Not disclosed
Details of issuance or disposal
ItemDetails
Type of issuance or disposal行使価額修正条項付新株予約権の行使停止要請
Intended allotteeName Long Corridor Alpha Opportunities Master Fund / Number of Shares Not disclosed, Name MAP246 Segregated Portfolio / Number of Shares Not disclosed, Name BEMAP Master Fund Ltd. / Number of Shares Not disclosed
Number of Stock Acquisition Rights発行総数:Not disclosed、未行使残:396,000個(普通株式39,600,000株)
Most recent equity financingTiming 8 December 2025 / Type 第三者割当による新株式及び第38回新株予約権(行使価額修正条項付)の発行 / Amount Not disclosed
Items this document does not state (24)
Number of shares to be issued or disposed ofIssue price and disposal priceTotal issue valueAmount of funds to be raisedEstimated issuance expensesSpecific use of fundsPayment dateIntended allottee's holding policyDilution RateTotal number of issued sharesBasis for determining the amount to be paidExercise priceExercise periodTransfer restriction periodConditions for lifting transfer restrictionsReason for acquisition without considerationCategories and Number of Persons CoveredTotal Stock-Based CompensationUnderwriter / lead underwriterOverallotmentStock Split RatioProcedures under the Corporate Code of ConductMajor shareholders after the offeringImpact on Business Performance

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

会社は行使停止要請の理由を記載していない。

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
新株予約権引受契約に基づく第38回新株予約権(行使価額修正条項付)の行使停止要請通知に関するお知らせ | OncoTherapy Science,Inc. (4564) timely disclosure | Komori